Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Stomach Cancer


 FDC                                                   gastric(62)
 _________________________________________________________________
  fluorouracil.... 300 mg/sqm IV days 1 to 5.
  adriamycin...... 40 mg/sqm IV day 1.
  cisplatin....... 60 mg/sqm IV day 1 with hydration.
  FREQUENCY....... Repeat cycle every 5 weeks.

  reference...
    Moertel CG.  Rubin J.  O'Connell MJ.  Schutt AJ.  Wieand HS. A 
    phase II study of combined 5-fluorouracil, doxorubicin, and 
    cisplatin in the treatment of advanced upper gastrointestinal 
    adenocarcinomas. Journal of Clinical Oncology.  4(7):1053-7, 
    1986 Jul. 
  abstract...
    In a phase II study of 67 patients with upper gastrointestinal 
    carcinomas and measurable disease without previous 
    chemotherapy, we have evaluated the combination of intensive 
    course 5-fluorouracil (5-FU) (300 mg/m2/d for five days) 
    doxorubicin (40 mg/m2 on day 1), and cisplatin (60 mg/m2 on 
    day 1). Courses were repeated every 5 weeks. Among 26 patients 
    with gastric carcinoma, a 50% regression rate was obtained 
    with a median survival for all patients of 9 months. Among 29 
    patients with pancreatic carcinoma, the regression rate was 
    21% and the median survival was 4 months. Regressions were 
    also observed in smaller numbers of patients with carcinomas 
    of the gallbladder and ampulla of Vater, as well as in 
    cholangiocellular carcinoma of the liver. Toxic reactions were 
    usually clinically tolerable and consisted primarily of 
    nausea, vomiting, stomatitis, diarrhea, leukopenia, and 
    alopecia. Phase III studies are in progress to place the value 
    of this experimental regimen into clinical perspective. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.